KOBLAN KENNETH S 4
4 · ALNYLAM PHARMACEUTICALS, INC. · Filed Dec 10, 2010
Insider Transaction Report
Form 4
KOBLAN KENNETH S
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2010-12-08+10,000→ 10,000 totalExercise: $9.14Exp: 2020-12-08→ Common Stock (10,000 underlying)
Footnotes (1)
- [F1]The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.